Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort - 21/06/19
![](/templates/common/images/mail.png)
on behalf of the
Groupe de Recherche sur l'Eczéma aTopique (GREAT), France
Abstract |
Background |
Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.
Objective |
We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.
Methods |
We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.
Results |
We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.
Limitations |
No control group, missing data.
Conclusion |
This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Le texte complet de cet article est disponible en PDF.Key words : adults, atopic dermatitis, biotherapy, conjunctivitis, dupilumab, eosinophilia
Abbreviations used : AD, AE, DLQI, EASI, EASI50, EASI75, IQR, SCORAD, SCORAD50, SCORAD75
Plan
For the French Group of Research and Study in Atopic Dermatitis, the French Society of Dermatology. |
|
Funding sources: None. |
|
Conflicts of interest: Dr Jachiet, Prof Bouaziz, Dr Lasek, Dr Du-Thanh, Dr Raison-Peyron, Dr Tetart, Dr Duval-Modeste, Prof Misery, Prof Richard, Dr Barete, and Prof Seneschal received personal fees from Sanofi Genzyme. Dr Reguiai received personal fees from Leo-Pharma, AbbVie Inc, and Sanofi Genzyme. Dr Nosbaum received research grants and personal fees from Sanofi Genzyme. Dr Morice received personal fees from Sanofi Genzyme, Novartis, and Janssen. Dr Soria received personal fees from Sanofi Genzyme and Novartis. Prof Lacour received personal fees from Sanofi Genzyme and personal fees and research grants from Regenron, United States. Prof Barbarot received personal fees from Sanofi Genzyme, Leo Pharma, Janssen, AbbVie, Bioderma, and Pierre Fabres. Prof Staumont-Sallé received personal fees from Sanofi Genzyme. Dr Faiz, Dr Giovannelli, Ms Podevin, Dr Ferrier le Bouëdec, Prof Aubin, Prof Dompmartin, Dr Droitcourt, Dr Arnault, Dr Delaunay, Dr Mahé, Dr Schoeffler, Dr Begon, Dr Walter-Lepage, Dr Dillies, Dr Rappelle-Duruy, Dr Bellon, Dr Beneton, and Dr Valois have no conflicts of interest to disclose. |
Vol 81 - N° 1
P. 143-151 - juillet 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?